# Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

> **NCT04504331** · PHASE1 · TERMINATED · sponsor: **Jennifer Lee Caswell-Jin** · enrollment: 4 (actual)

## Conditions studied

- Breast Cancer
- HER2-negative Breast Cancer
- ER Positive Breast Cancer
- PR-Positive Breast Cancer

## Interventions

- **DRUG:** Infigratinib
- **DRUG:** Tamoxifen
- **DRUG:** Omnipaque 350
- **DRUG:** Iopamidol
- **DIAGNOSTIC_TEST:** Computed tomography (CT)

## Key facts

- **NCT ID:** NCT04504331
- **Lead sponsor:** Jennifer Lee Caswell-Jin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-13
- **Primary completion:** 2021-10-22
- **Final completion:** 2021-10-22
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Drug manufacturer decision to terminate development.
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504331, "Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04504331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*